Cite
MLA Citation
A. Necchi et al.. “2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study.” European journal of cancer, vol. 51, n.d., pp. S528–. http://access.bl.uk/ark:/81055/vdc_100030628262.0x00000d